The role of erythropoietin and other growth factors in transfusion medicine.
Klingemann
H G
HG
Division of Hematology, British Columbia Cancer Agency, Vancouver, Canada.
Shepherd
J D
JD
Eaves
C J
CJ
Eaves
A C
AC
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000740:Anemia / Q000209:etiology / Q000628:therapy; D000970:Antineoplastic Agents / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D004341:Drug Evaluation; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005544:Forecasting; D016298:Hematopoietic Cell Growth Factors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications; D009190:Myelodysplastic Syndromes / Q000628:therapy; D009503:Neutropenia / Q000209:etiology / Q000628:therapy; D011832:Radiation Injuries / Q000150:complications; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors; D007155:Immunologic Factors; D011993:Recombinant Fusion Proteins; D004921:Erythropoietin